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This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).SUMMARYControversy surrounds reports describing the derivation of human trophoblast cells from placentas and embryonic stem cells (ESC),
partly due to the difficulty in identifying markers that define cells as belonging to the trophoblast lineage. We have selected criteria
that are characteristic of primary first-trimester trophoblast: a set of proteinmarkers, HLA class I profile,methylation of ELF5, and expres-
sion of microRNAs (miRNAs) from the chromosome 19 miRNA cluster (C19MC). We tested these criteria on cells previously reported to
show some phenotypic characteristics of trophoblast: bone morphogenetic protein (BMP)-treated human ESC and 2102Ep, an embry-
onal carcinoma cell line. Both cell types only show some, but not all, of the four trophoblast criteria. Thus, BMP-treated human ESC
have not fully differentiated to trophoblast. Our study identifies a robust panel, including both protein and non-protein-codingmarkers
that, in combination, can be used to reliably define cells as characteristic of early trophoblast.INTRODUCTION
One of the key early events in the establishment of preg-
nancy is the development of trophoblast subpopulations
from the trophectoderm (TE) of the implanting blastocyst
(Rossant, 2001). Ethical and logistical difficulties limit our
knowledge of these earliest stages of placentation in hu-
mans. In the mouse, trophoblast stem cells (TSC) have
been isolated, but there is still no reliable source of such
cells for humans. While it is possible to isolate primary
trophoblast from human first-trimester placentas, they
rapidly differentiate and do not proliferate in vitro.
Attempts have beenmade to overcome this problem by ob-
taining trophoblast cell lines from early placentas by trans-
formation, or by driving human embryonic stem cells
(hESC) along the trophoblast differentiation pathway (Xu
et al., 2002; Nagamatsu et al., 2004; Harun et al., 2006;
James et al., 2007; Genbacev et al., 2011; Marchand et al.,
2011; Takao et al., 2011; Udayashankar et al., 2011; Amita
et al., 2013). However, all these strategies have been
plagued with difficulties in identifying the cells as ‘‘tropho-
blast’’ in culture (Roberts et al., 2014). In vivo, trophoblast
cells can be identified by their anatomical location and
the expression of particular markers. In vitro, there is a
lack of consensus about the best criteria to use to define
trophoblast.
A distinctive feature of trophoblast is its profile of human
leukocyte antigen (HLA) class I expression. There are two
main differentiation pathways in human placentas, villousStem Ce(VCT) and extravillous (EVT) cytotrophoblast. VCTs fuse to
form an overlying syncytiotrophoblast (ST), and EVTs form
multinucleated placental bed giant cells deep in the
decidua and myometrium. ST and VCT are HLA class I
null, whereas EVT express HLA-C and -E molecules, and
HLA-G, which is uniquely expressed by trophoblast (Apps
et al., 2009). In contrast, most normal somatic cells are
HLA class I positive and express HLA-A, -B, -C, and -E
(Wei and Orr, 1990). Only neurons, glial cells, germ cells,
hepatocytes, and exocrine pancreas are negative (Fleming
et al., 1981; Anderson et al., 1984; Lampson and Hickey,
1986; Jalleh et al., 1993). Thus, human first-trimester
trophoblast cells never express HLA-A and -B, and are the
only cells that normally express HLA-G.
The most commonly used ‘‘trophoblast’’ markers re-
ported in the literature are cytokeratin 7 (KRT7), HLA-G,
and human chorionic gonadotropin (hCG), but these are
either not specific to all trophoblast cells or are expressed
in other cell types. Several of the transcription factors
(TF) that define the transcriptional network of mouse TSC
have also been used (e.g. CDX2 and EOMES) (Senner and
Hemberger, 2010). However, it is not known whether the
same network operates in humans or what the pattern of
expression is in normal first-trimester trophoblast popula-
tions (Table S1).
ELF5 is a TF that is expressed in mouse TSC to sustain
their potential for self-renewal and commitment to the
extraembryonic lineage (Donnison et al., 2005; Ng et al.,
2008). In mice, the promoter of Elf5 is hypermethylatedll Reports j Vol. 6 j 257–272 j February 9, 2016 j ª2016 The Authors 257
in ESC and hypomethylated in TSC (Ng et al., 2008). In
human early placental tissue, the ELF5 promoter is
mostly hypomethylated (Hemberger et al., 2010). Thus,
the lack of methylation of the ELF5 promoter could poten-
tially be an additional marker to define trophoblast,
although it is still unknown whether ELF5 hypomethyla-
tion is present specifically in trophoblast or in other
placental cell types.
Another possible candidate for defining trophoblast is
the expression of specific non-protein-coding microRNAs
(miRNAs), in particular the chromosome 19miRNA cluster
(C19MC) that is located in the leukocyte receptor complex
on chromosome 19q13.41 (Bentwich et al., 2005). C19MC
miRNAs are primate specific and maternally imprinted,
with expression normally restricted only to the placenta
and hESC (Bentwich et al., 2005; Laurent et al., 2008; Bor-
tolin-Cavaille´ et al., 2009; Noguer-Dance et al., 2010).
C19MC is the largest cluster of miRNAs in humans and is
highly expressed in human trophoblast cells (Bortolin-
Cavaille´ et al., 2009; Donker et al., 2012).
In this study we test these four criteria, which include
both protein and non-protein-coding markers, using pri-
mary human trophoblast.We focused on the first trimester,
as this is when placental development occurs. We show
that, by using these criteria in combination, reliable identi-
fication of genuine trophoblast is possible. As proof of prin-
ciple, we then tested these four diverse characteristics
(expression of trophoblast protein markers and C19MC
miRNAs, HLA class I profile, and methylation status of
ELF5 promoter) on two cell types: 2102Ep, an embryonal
carcinoma (EC) cell line, and trophoblast-like cells induced
from BMP4-treated hESC. Here, we show that both cell
types show some properties typical of trophoblast, but
neither displays all four characteristics. We propose that
this classification system will provide a stringent method
to define human trophoblast cells in vitro.RESULTS
Lack of Consensus over Definition of Trophoblast
We previously studied some ‘‘trophoblast’’ cell lines but
were unable to confidently identify any of them as tropho-
blast (King et al., 2000). We have now updated these find-
ings and collated published criteria used to characterize
‘‘trophoblast’’ cells derived from placentas or other cell
types (hESC and fibroblasts) (Tables 1 and 2). Importantly,
none of the markers are unique to trophoblast, as high-
lighted in a recent debate (Roberts et al., 2014). The most
commonly used markers are KRT7, HLA-G, and hCG.
KRT7 was proposed as a marker because trophoblast is the
only epithelial cell in the placenta. However, many other
epithelial cells are also KRT7+, notably uterine glandular258 Stem Cell Reports j Vol. 6 j 257–272 j February 9, 2016 j ª2016 The Auepithelium that can contaminate first-trimester cell isolates
from normal pregnancies (Ramaekers et al., 1987; Muhl-
hauser et al., 1995; Blaschitz et al., 2000; King et al.,
2000). HLA-G expression is restricted to EVT and not
VCT; therefore, it is only of use in identifying the EVT sub-
population (Apps et al., 2009). Furthermore, due to the
close homology of HLA-G to other HLA class I molecules,
cross-reactivity of antibodies and primers is always a prob-
lem (Apps et al., 2008). HCG, secreted only by the ST, with
some contribution from the hyperglycosylated form from
EVT (Cole, 2010), can also be secreted by normal somatic
tissues, particularly from the pituitary gland, and by a
range of tumors (Cole, 2012). Both HLA-G and hCG there-
fore define the two main trophoblast differentiation path-
ways, EVT and ST, respectively, and would be useful in
studying in vitro differentiation, but not as core markers
of all trophoblast.
KRT7, GATA3, and TFAP2C Are Good Markers for
Mononuclear Trophoblast
To find better markers, we chose proteins that are only ex-
pressed by trophoblast and not by other placental cell
types. KRT7 is present in all trophoblast cells but not in
the villous stromal core (Figure 1A; n = 6 donors) (Muhl-
hauser et al., 1995; Blaschitz et al., 2000). TF activator
protein-2 gamma (TFAP2C) and GATA–binding protein 3
(GATA3) were highly transcribed in all trophoblast cells
in our previous microarray study that compared EVT and
VCT (Apps et al., 2011). Immunostaining confirms that
TFAP2C and GATA3 proteins are expressed in all human
trophoblast cells except ST (Figure 1A; n = 6 donors) (Kuck-
enberg et al., 2010, 2012; Biadasiewicz et al., 2011).
We therefore used KRT7 as a pan-trophoblast marker,
and TFAP2C and GATA3 as markers for mononuclear
trophoblast.
Methylation of the ELF5 Promoter
The ELF5 promoter is hypomethylated in mouse TSC and
human placental cells but hypermethylated in mouse
and human ESC (Ng et al., 2008; Hemberger et al., 2010).
To investigate whether the ELF5 promoter is methylated
specifically in primary human trophoblast, we performed
bisulfite sequencing on first-trimester epidermal growth
factor receptor (EGFR)+ VCT and HLA-G+ EVT sorted by
flow cytometry, and compared themwith placentalmesen-
chymal cells that were passaged several times after isolation
and contain no trophoblast cells. The ELF5 promoter is hy-
permethylated in the mesenchymal cells but not in either
trophoblast subpopulation, indicating that, compared
with cells for the villous core, hypomethylation of the
ELF5 promoter is indeed restricted to trophoblast in first-
trimester human placentas (Figures 1B and S1A; n = 8
data points from two donors).thors
Figure 1. Features of Primary Tropho-
blast Cells
(A) Expression of KRT7, TFAP2C, and GATA3
are good markers for mononuclear tropho-
blast (n = 6 donors) (gestational age
8–12 weeks). ST, syncytiotrophoblast; VCT,
villous cytotrophoblast; EVT, extravillous
cytotrophoblast. Scale bar, 100 mm.
(B) Methylation status of individual CpG
sites at the ELF5 promoter in VCT and EVT
isolated by flow cytometric sorting (Fig-
ure S1A), compared with placental mesen-
chymal cells (PMC). Percentages show the
proportion of methylated (closed circles) to
non-methylated (open circles) CpG sites
(n = 8 data points for each CpG per donor,
samples from two donors) (results from one
donor shown; both showed similar results).
(C) Expression of four C19MC miRNAs in
choriocarcinoma cell lines (JAR, JEG-3),
primary trophoblast (M25T, M26T, M27T)
(Figure S1B), embryonal carcinoma (EC)
lines (2102Ep, NCCIT), hESC (H9 hESC),
seminoma (TCam2), yolk sac tumor (GCT44,
1411H), and gonads (ovary, testes) (n = 3
independent experiments). Results are
normalized to levels of miR-103a and
plotted against the expression level for JAR
cells. Normalized results are multiplied
10,000–100,0003 to ensure all logged
values are positive. Red solid line: 2102Ep
levels; red dotted line: hESC levels. Error
bars represent SE. ND, not detectable.Expression of miRNAs from the C19MC
To confirm the expression of C19MC miRNAs in primary
trophoblast, we compared levels of miRNAs between
trophoblast and cell lines with known levels of C19MC
miRNAs, as controls and to assess the robustness of our
assay. Four C19MC miRNAs (hsa-miR-525-3p, -526b-3p,
-517-5p, and 517b-3p) were chosen due to their reported
expression in trophoblast, hESC, and EC (Cao et al., 2008;
Palmer et al., 2010; Donker et al., 2012). The samples used
were: primary first-trimester trophoblast (n = 3 donors)
(M25T, M26T, M27T) (Figure S1B), normal gonads (testis
and ovary), and malignant germ cell tumor cell lines;
choriocarcinoma subtype (JEG-3, JAR), EC (2102Ep,
NCCIT), seminoma (TCam-2), and yolk sac tumors
(GCT44, 1411H) (Palmer et al., 2010; Novotny et al.,Stem Ce2012). Because hESC also expresses C19MC miRNAs, the
H9 hESC line was also included (Bar et al., 2008; Cao
et al., 2008; Laurent et al., 2008; Li et al., 2009; Ren et al.,
2009).
Levels of miR-525-3p, -517-5p, and -517b-3p measured
by qRT-PCR are substantially higher (3- to 10,000-fold
difference) in primary trophoblast cells and choriocarci-
noma lines compared with the other cells (Figure 1C;
repeated three times). 2102Ep, NCCIT, TCam-2, and H9
hESC show moderate expression levels, significantly
higher than the other cancer cell lines, but at least 10-
to 1,000-fold lower than bona fide trophoblast. Levels
of miR-526b-3p are more variable, but show a similar
trend (Figure 1C). Yolk sac tumor and EC lines have the
lowest and highest levels of miRNAs among the germll Reports j Vol. 6 j 257–272 j February 9, 2016 j ª2016 The Authors 259
Figure 2. Characteristics of First
Trimester Mononuclear Trophoblast Cells
Flowchart depicting the characteristics of
mononuclear trophoblast cells from first-
trimester placentas. +ve, positive; -ve,
negative. VCT, villous cytotrophoblast; EVT,
extravillous cytotrophoblast.cell tumor lines, respectively, reflecting our microarray
results and indicating that our assay is robust (Palmer
et al., 2010; Novotny et al., 2012). Thus, very high levels
of C19MC miRNAs are indeed characteristic of first-
trimester trophoblast.
Expression of HLA Class I Molecules
The fourth marker we used is surface expression of HLA
class I molecules. We have already extensively investi-
gated the unique HLA class I profile on first-trimester
trophoblast cells: VCT do not express any HLA class I mol-
ecules and EVTonly express HLA-C, -G, and -E. No tropho-
blast cells express HLA-A or -B or class II molecules (Apps
et al., 2009).
On the basis of these findings we have generated a classi-
fication system (Figure 2) to aid in the identification of
mononuclear trophoblast cells from early in gestation.
Multinucleated cells could be ST or placental bed giant
cells. ST are HLA class I negative and express aminopepti-
dase A, placental leucine aminopeptidase, hCG, and preg-
nancy-specific glycoproteins (Beck et al., 1986; Takayama
et al., 1989; Zhou et al., 1997; Hariyama et al., 2000; Yama-
hara et al., 2000; Ino et al., 2003; Ito et al., 2003). Placental
bed giant cells are strongly HLA-G+ and hPL+ (Al-Lamki
et al., 1999).
Testing the Suitability of These Criteria to Reliably
Distinguish Trophoblast-like Cells from Bona Fide
Trophoblast
EC Cells
2102Ep EC cells express the highest levels of C19MC miR-
NAs among the ‘‘non-trophoblast’’ lines and are therefore
closest to trophoblast in this respect. Furthermore, EC
can contain both embryonic and extraembryonic ele-
ments; some express CDX2 and TFAP2C and high levels
of C19MC miRNAs, and differentiate into hCG-secreting
multinucleated cells, all characteristics of trophoblast260 Stem Cell Reports j Vol. 6 j 257–272 j February 9, 2016 j ª2016 The Au(Damjanov and Andrews, 1983; Hoei-Hansen et al., 2004;
Przyborski et al., 2004; Noguer-Dance et al., 2010; Palmer
et al., 2010; Lee et al., 2012; Novotny et al., 2012). Thus,
we tested whether cultures of 2102Ep could contain cells
of the trophoblast lineage.
Staining for KRT7, TFAP2C, and GATA3, with JEG-3
cells as positive control, show that 2102Ep cells are negative
for KRT7 and GATA3, and positive for TFAP2C (Figure 3A;
n = 3). The CpGs in the ELF5 promoter in 2102Ep cells are
mainly methylated, like villous mesenchymal cells (Fig-
ure 3B). Flow cytometric analysis using W6/32, a pan-HLA
class Imonoclonal antibody (mAb), shows that 2101Ep cells
clearly expressHLA class Imolecules, unlikeVCT (Figure 3C;
n = 3). EVT and JEG-3 cells express HLA-G, but 2102Ep cells
are HLA-G negative (Figures 3C and 3D; n = 3). 2102Ep cells
express the classical HLA class I molecules, HLA-A and -B, in
contrast to EVT, althoughHLA-B expression is very low (Fig-
ures 3C and 3D). Overall, other than being TFAP2C+ and
having moderate levels of C19MC miRNAs, 2102Ep do
not resemble primary trophoblast cells.
BMP-Treated hESC
It is still controversial whether BMP-treated hESC can
differentiate into trophoblast, and we therefore used this
as our second, more powerful test model (Xu et al., 2002;
Bernardo et al., 2011; Amita et al., 2013). CA1 and H1
hESC lines were cultured either with fibroblast growth fac-
tor 2 (FGF2) as a control, or with BMP4, A83-01, and
PD173074 (BAP), as the addition of these ALK and FGF re-
ceptor inhibitors enhances this conversion (Amita et al.,
2013). Both hESC lines showed similar results.
Cells maintained in FGF2 are small, round, and overcon-
fluent by day 4 (Figure S1A). In contrast, BAP-treated cells
have a flattenedmorphology after 2 days, and by the fourth
day aggregates of cells overlying the adherent cells appear
and persist until the cells are harvested on day 6 (Fig-
ure S2A). Their mononuclear morphology was confirmed
by staining with a universal membrane dye (Figure S2B).thors
Figure 3. 2102Ep Cells Are Unlike Primary Trophoblast Cells
(A) 2102Ep cells were stained by immunocytochemistry for GATA3,
TFAP2C, and KRT7 with JEG-3 cells as a positive control. Flow cy-
tometry confirmed that the few cells staining positive for KRT7
(arrows) were dead (data not shown) (n = 3 independent experi-
ments). Scale bar, 200 mm.
(B) Methylation status of the ELF5 promoter in 2102Ep EC (closed
circles, methylated CpG; open circles, non-methylated CpG).
(C) HLA profile of 2102Ep (n = 3 independent experiments).
(D) Positive controls for HLA-G and HLA-B7 staining were JEG-3 and
721.221-HLA-B7, respectively.Aggregates form about 3.94% ± 0.79% (mean ± SE) of the
total cells present.
We found upregulation of CDX2 and CGb, and downre-
gulation of EOMES as previously reported, while CHRD
andTBX6 expression levels remained the same (Figure S2C)
(Amita et al., 2013). Although all BAP-treated hESC are
KRT7+, only the cell aggregates are strongly positive for
TFAP2C and GATA3, with weaker expression in the
adherent cells (Figure 4A; n = 3). FGF2-treated hESC are
negative for all three markers. These findings were also
confirmed by qRT-PCR (Figure 4B; n = 3). Downregulation
of POU5F1 andNANOG indicates that BAP-treated hESC are
no longer pluripotent (Figure 4B). With regard to ELF5Stem Cemethylation and expression, both CA1 and H1 hESC
grown in control FGF2 were heavily methylated. In
contrast, with BAP-treated hESC a significant degree of de-
methylation from more than 80% to around 30% over the
6-day differentiation period is seen (Figures 4C and 4D).
The bisulfite-sequenced clones did not separate into meth-
ylated and unmethylated alleles, suggesting that demethy-
lation occurs in a stochastic manner in both the flat cells
and the aggregates. qRT-PCR shows that transcript levels
of ELF5 were increased in BAP-treated hESC, but levels
were 27- to 70-fold lower than that of JEG-3 (Figure 4B).
C19MC miRNA levels in BAP-treated hESC are lower by
5- to 50-fold compared with those in FGF2-treated hESC,
and 400- to 4,000-fold lower compared with JEG-3, repre-
sentative of the C19MC levels in primary trophoblast (Fig-
ure 5A; n = 3). AlthoughBAP- and FGF-treated hESC express
HLA class I molecules, neither H1 or CA1 express HLA-G,
unlike either VCT or EVT (Figures 5B and 5C; n = 3). H1
(but not CA1) has the HLA-A2 allele, and BAP treatment
maintains HLA-A2 expression (Figure 5D; n = 3). Both
FGF2- and BAP-treated hESC express HLA-B (Figure 5E).
The characterization of these cells is summarized in Table
S2. Taken together, we conclude from these results that
although both 2102Ep- and BAP-treated hESC show some
features similar to those of first-trimester trophoblast,
when all the characteristics are studied in combination
they do not truly resemble either VCT or EVT.DISCUSSION
The main obstacle in defining trophoblast cell fate in cell
lines in vitro has been that there is no marker exclusive to
trophoblast cells that could serve as an unambiguous
readout of cell lineage allocation. Therefore, our aim in
this study was to identify a set of criteria that would allow
cells to be rigorously assigned to the trophoblast lineage.
These criteria have been defined using first-trimester
primary trophoblast, the period of gestation when
exuberant trophoblast proliferation and development of
the placenta occurs. Furthermore, obstetric outcome is
affected by placental dysfunction before 10 weeks’ gesta-
tional age (Smith, 2010). In future, analysis of trophecto-
derm and trophoblast later in gestation can be done to
confirm that these criteria define trophoblast throughout
pregnancy.
Our tables illustrate that many of the markers currently
in use are either only present in some trophoblast subtypes
(e.g. CDX2, ELF5, HLA-G), and/or are not specific to
trophoblast (e.g. KRT7, CDX2, EOMES). Therefore, using
information from our previous microarray data of fluores-
cence-activated cell-sorted trophoblast cells, we selected
genes involved in the transcriptional network that drivell Reports j Vol. 6 j 257–272 j February 9, 2016 j ª2016 The Authors 261
Figure 4. BAP- and FGF-Treated hESC Are
Unlike Primary Trophoblast Cells
(A) Co-immunofluorescence of KRT7,
TFAP2C, and GATA3 in H1 and CA1 hESC
(n = 3 independent experiments). Scale bar,
100 mm.
(B) Expression levels of POU5F1, NANOG,
TFAP2C, GATA3, and ELF5 transcripts in BAP-
and FGF2-treated hESC and JEG-3 cells
(n = 3 independent experiments). Error bars
represent SE. ND, not detectable. Assessed
using paired two-tailed Student’s t test.
*p % 0.05, **p % 0.01, ***p % 0.001,
****p% 0.0001
(C) Methylation status of the ELF5 promoter
in BAP or FGF2-treated CA1 hESC (closed
circles, methylated CpG; open circles, non-
methylated CpG).
(D) Pyrosequencing shows that the ELF5
promoter in BAP-treated H1 hESC cells is
also hypomethylated, compared with FGF-
treated H1 hESC. See also Figure S2.murine TSC, and show that TFAP2C and GATA3 are ex-
pressed in all mononuclear trophoblast cells, providing
useful additional markers (Biadasiewicz et al., 2011; Kuck-
enberg et al., 2012).
We have previously used the distinctive HLA class I pro-
file of VCTand EVT to characterize BMP-treated hESC (Ber-
nardo et al., 2011). As a further refinement, we now show
that we can distinguish between products of different
HLA class I loci, particularly HLA-G and HLA-A and -B.
With knowledge of the HLA class I locus-specific alleles pre-
sent in 2102Ep and the hESC lines, we selected mAbs that
bind specifically to different HLA allotypes (Brodsky et al.,
1979; Parham and Brodsky, 1981; Josephson et al., 2007;262 Stem Cell Reports j Vol. 6 j 257–272 j February 9, 2016 j ª2016 The AuNIH, 2009). Other mAbs are available that bind various
combinations of HLA-A and -B allotypes, and HLA-Bw4
and -Bw6 epitopes (Koene et al., 2006; Schumm et al.,
2007; Duquesnoy et al., 2013). With HLA genomic typing
of the test cells and selection of appropriate antibodies, it
should generally be possible to make a comprehensive
comparison to discern whether if HLA-A, -B, or -G mole-
cules are expressed. HLA-G is never expressed together
with HLA-A and -B in normal trophoblast. Flow cytometry
allows analysis of the frequency of subpopulations, pro-
viding another advantage of screening the HLA class I
profile of putative trophoblast cells. Indeed, no subpopula-
tion of either HLA class I negative or HLA-G positive cellsthors
Figure 5. Expression of C19MC miRNAs
and HLA Class I Molecules on BAP- and
FGF-Treated hESC
(A) The expression of four C19MC miRNAs is
compared between BAP- and FGF-treated
hESC controls. The positive control, JEG-3
cells, show C19MC levels characteristic of
normal trophoblast. Mammary gland is
included as negative control (n = 3 inde-
pendent experiments). Error bars represent
SE. ND, not detectable.
(B–E) HLA class I expression by 2102Ep EC
and BAP-treated or control FGF-treated
hESC. mAb W6/32 detects all HLA class I
molecules (B), HLA-G (C), HLA-A (D), and
HLA-B (E) on BAP-treated and FGF2-treated
cells (n = 3 independent experiments).was detected in BAP-treated hESC, highlighting the power
of flow cytometric analysis. This compares with the diffi-
culties in interpreting immunofluorescence images of
small cellular clusters that may not be representative of
the whole population.
We also show that hypomethylation of the ELF5 pro-
moter is specific for normal VCT and EVT but not
for non-trophoblast placental villous mesenchymal cells
(Hemberger et al., 2010). The ELF5 promoter is hyperme-
thylated in the following cells: 2102Ep cells, hCG-secreting
hESC, and BMP4-treated hESC, TCL1, SWAN-71, and HTR-
8/SVneo (Hemberger et al., 2010; Bernardo et al., 2011;
Novakovic et al., 2011; Sarkar et al., 2015). Fibroblasts re-Stem Ceprogrammed with CDX2, EOMES, and ELF5 have some
characteristics of trophoblast (KRT7, GATA3, and HLA-G
expression), but the ELF5 hypermethylation pattern is
similar to that of the parental fibroblasts (Chen et al.,
2013a). This differential methylation between hESC and
trophoblast suggests that, as in mice, the epigenetic status
of human ELF5 segregates the embryonic and extraembry-
onic lineages. We find that despite partial hypomethyla-
tion in BAP-treated hESC, ELF5 expression levels remain
very low, as in mouse ESC (Cambuli et al., 2014). This is
also similar to EVT, where ELF5 is hypomethylated but
only expressed at low levels, indicating that either ELF5 is
silenced by other mechanisms, or that the transcriptionalll Reports j Vol. 6 j 257–272 j February 9, 2016 j ª2016 The Authors 263
Table 1. Summary of Markers Used in the Literature to Characterize ‘‘Trophoblast’’ Isolated from Placentasa
References
Primary Placental Cells Immortalized Cells from Human Placentas
No. of Papers
Using Marker
Genbacev
et al.,
2011
James
et al.,
2007
Nagamatsu
et al.,
2004
Takao
et al.,
2011
BP-TERT1 HPT-8 ACH-3P HChEpC1b SWAN 71
Wang
et al.,
2006
Zhang
et al.,
2011
Hiden
et al.,
2007
Omi
et al.,
2009
Straszewski-
Chavez et al.,
2009
Positive ‘‘Trophoblast’’ Markers
KRT7 C C C C C C C, W, R C, W 8
KRT8 C 1
KRT18 C 1
GATA3 C 1
EOMES C 1
CDX2 C 1
GCM1 C 1
ID2 R, W 1
Integrin a1 C F C R R 5
Integrin a5 C F R 3
Integrin a6 C F R R 4
Integrin b1 C R 2
Geminin C 1
Neonatal Fcg C 1
Integrin a4 C 1
N-cadherin C 1
Integrin avb3 C 1
PHLDA2 R, W 1
BMP4 R, W 1
Integrin avb6 C 1
Tenascin C 1
CD9 C C, F C C 4
G11 C 1
CSH1 C 1
FGFR3 R 1
EGFR C 1
SDF1 C 1
MMP2 W G 2
MMP9 W G 2
IGF2R R 1
E-cadherin C, W 1
(Continued on next page)
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Table 1. Continued
References
Primary Placental Cells Immortalized Cells from Human Placentas
No. of Papers
Using Marker
Genbacev
et al.,
2011
James
et al.,
2007
Nagamatsu
et al.,
2004
Takao
et al.,
2011
BP-TERT1 HPT-8 ACH-3P HChEpC1b SWAN 71
Wang
et al.,
2006
Zhang
et al.,
2011
Hiden
et al.,
2007
Omi
et al.,
2009
Straszewski-
Chavez et al.,
2009
hCG C, E C R RI b C E 7
Progesterone RI 1
PLAP C C, R 2
Prostaglandin E2 RI 1
Prolactin RI 1
Placental lactogen C 1
Fetal fibronectin E 1
Markers Absent from Normal Trophoblast
POU5F1 (OCT3/4) C 1
Vimentin C C C C C C, W, R W 7
ZO-1 C 1
GATA4 C 1
Nestin C 1
CD45 C 1
CD68 C 1
FSA W 1
HLA Molecules 1
HLA-G C C C, F C C C, F C, R W 8
Other Assays
Microarray yes 1
Cytokine array yes 1
Resistance to
Fas-mediated
apoptosis
yes 1
Sensitive to
TNFa-mediated
apoptosis
yes 1
Invasion assay transwell transwell 2
Syncytialization yes yes 2
Morphology epithelial 1
R, qRT-PCR or northern blot; C, immunocytochemistry; F, flow cytometry; E, ELISA; W, western blot; G, gel zymography, RI, radioimmunoassay.
aPapers were reviewed since our previous report (King et al., 2000).
bMethod not known.
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Table 2. Markers Used in the Literature to Characterize ‘‘Trophoblast’’ Cells Induced From Non-placental Cells
References
Chen et al.,
2013b
Xu et al.,
2002
Marchand
et al., 2011
Amita et al.,
2013; Telugu
et al., 2013
Udayashankar
et al., 2011; Harun
et al., 2006
Chen et al.,
2013a
No. of Papers
Using Marker
Positive ‘‘Trophoblast’’ Markers
KRT7 C R R, C R, F C C 6
GATA3 R R 2
ELF5 R R 2
EOMES R R, W R C 4
CDX2 R R, C R, C, W R C, R 5
TEAD4 R 1
ID2 R 1
SMAD9 R 1
HAND1 R R 2
Integrin a1 C 1
GCM1 R 1
HASH2 R 1
MET R 1
ESRRb R 1
CD9 R R 2
MMP2 C, W, GZ 1
MMP9 C, W, GZ 1
VE-cadherin C 1
hCG E R, C, F, E E, R E, R, C C, E E 6
Estradiol E E E 3
Progesterone E E 2
PGF E, R 1
P4 E 1
Markers Absent in Normal Trophoblast
NANOG R R R R 4
POU5F1 (OCT3/4) R R R, C R R 5
SOX2 R R R 3
CER1 R 1
LEFTY R 1
T (brachyury) R, C, W 1
TBX R 1
TRA-1-60 C 1
(Continued on next page)
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Table 2. Continued
References
Chen et al.,
2013b
Xu et al.,
2002
Marchand
et al., 2011
Amita et al.,
2013; Telugu
et al., 2013
Udayashankar
et al., 2011; Harun
et al., 2006
Chen et al.,
2013a
No. of Papers
Using Marker
SSEA3 or 4 C 1
FGF2 R 1
SOX17 C 1
GATA4 C R 2
SALL4 R 1
Other Markers
FOXD3 R R 2
TERT R R R 3
HLA Molecules
HLA-A R 1
HLA-B R 1
W6/32 F 1
HLA-G C R R R, W, C R, C, F 5
Other Assays
ELF5 methylation yes 1
Microarray yes yes yes yes 4
Invasion assay transwell transwell co-cultures
transwell
transwell 4
Syncytialization yes yes yes 3
Morphology cobblestone 1
R, paper studied gene using qRT-PCR or northern blot; C, immunocytochemistry; F, flow cytometry; E, ELISA; W, western blot; GZ, gel zymography, RI, radio-
immunoassay.machinery for its activation is not in place. Overall, this is
in line with the commonly accepted view that promoter
hypomethylation is necessary but not sufficient for gene
activation (Deaton and Bird, 2011). Thus, both themethyl-
ation status of ELF5 and its expression levels are useful as
trophoblast identifiers. The methylation status of other
genes (e.g. the promoters of CGB are hypomethylated in
trophoblast) compared with other cell types might serve
as additional trophoblast markers (Novakovic et al., 2011).
We have now added another marker for trophoblast, the
expression of high levels of C19MCmiRNAs, which is char-
acteristic of primary trophoblast and choriocarcinoma cells
(10- to 10,000-fold higher expression of these miRNAs
compared with other cells including hESC and EC).
Because levels of C19MC were much lower in hESC than
in trophoblast cells, we would predict upregulation if
trophoblast lineage differentiation occurs. However, we
observed the opposite, with downregulation in BAP-treatedStem CehESC. It is essential to include primary trophoblast or
choriocarcinoma cells as positive controls for the analysis
of C19MC and ELF5 expression levels and appropriate
negative controls, such as leukocytes. To summarize, our
results show that very high expression of C19MC miRNAs
is a hallmark of first-trimester trophoblast.
Importantly, becausenoneof thesemarkers are specific for
trophoblast or trophoblast populations in general, they
must be used in combination. For example, SWAN-71
and HTR8/SVneo, two widely used ‘‘trophoblast’’ cell lines,
are hypermethylated at the ELF5 promoter, HTR8/SVneo
does not express C19MC miRNAs (Hemberger et al., 2010;
Donker et al., 2012; Morales-Prieto et al., 2012), and the
HLA profile is unlike either VCT or EVT (King et al., 2000).
Similarly, we show that BAP-treated hESC display only
some of our trophoblast markers (aggregates of cells with
TFAP2C and GATA3 expression and partial hypomethyla-
tion of ELF5 promoter). In contrast, their HLA class Ill Reports j Vol. 6 j 257–272 j February 9, 2016 j ª2016 The Authors 267
expressionpattern and the decreasedC19MCexpression are
not typical ofprimary trophoblast. The aggregates appearing
in BAP-treated cultures are epithelial cells, but their actual
identity requires further work. Nonetheless, we can
conclude that BAP-treated hESC do not fully differentiate
into cellswith all the characteristics of first-trimester tropho-
blast cells.
Much of the controversy surrounding studies on human
trophoblast in vitro has arisen because of difficulties in
definitive identification of the cell lines as bona fide tropho-
blast. Introduction of the robust classification system we
have developed here, using a diverse panel of protein and
non-protein coding markers, may lead to a consensus on
the best criteria to identify trophoblast derived from first-
trimester placentas or non-trophoblast sources.EXPERIMENTAL PROCEDURES
Ethical Approval
Cambridge Research Ethics Committee approved this study (04/
Q0108/23). Informed written consent was obtained from all
donors.
Isolating Placental Cells
Primary trophoblast was isolated from three first-trimester pla-
centas, as previously described (Male et al., 2010). In brief, the
chorionic villi were scraped from the membranes and digested in
0.2% trypsin, and placental cells were collected from the resulting
cell suspension by density gradient using Lymphoprep (Axis-
shield, #1114544). The proportion of trophoblast in M25T (gesta-
tional age [GA] 8 weeks), M26T (GA 9 weeks), and M27T (GA
12 weeks) is 23%, 27%, and 41% respectively, based on KRT7
expression by flow cytometry (Figure S2B). Each sample contained
6%–40% CD45+ leukocytes, which are negative for C19MC miR-
NAs (Bortolin-Cavaille´ et al., 2009).
Toobtainplacentalmesenchymal cells, after thefirst trypsindiges-
tion to release trophoblast cells we further incubated the residual
tissue from one donor in collagenase for 20 min at 37C. The
disaggregated mesenchymal cells from this second digestion were
pelleted and the red blood cells removed by Lymphoprep, and
cultured in 10% fetal calf serum (FCS)/DMEM with 2 mM L-gluta-
mine and antibiotics. DNAwas extracted after the third passage.
Cell Lines and Culture Conditions
All cell lines were usedwithin 6months of purchase fromATCC, or
profiled by short tandem repeat typing, as described by Palmer
et al. (2010). The culture conditions and hESC differentiation pro-
tocol are listed in Supplemental Experimental Procedures.
qRT-PCR of miRNA
Cell lines (n = 3 different passages) and primary placental
cells (n = 3 donors) were lysed in TRIzol reagent (Life Technologies
#15596-026). Total RNA was purified according to the manu-
facturer’s protocol. RNA of ovaries (#AM6974) and testes
(#AM7972) was purchased from Ambion.268 Stem Cell Reports j Vol. 6 j 257–272 j February 9, 2016 j ª2016 The AuTo quantify C19MC miRNAs, we adapted a previously published
method (Chen et al., 2005). RNA (10 ng) in 15 ml reaction mixture
was converted into cDNA using RT primers (50 nM) that were com-
plementary to eachmiRNAwith a TaqManMicroRNA Reverse Tran-
scription Kit (Life Technologies #4366596). Primers were designed
using miRNA Primer Design Tool by Astrid Research (see Supple-
mental Experimental Procedures) (Czimmerer et al., 2013). The
cDNAs were quantified by qRT-PCR with Fast SYBR Green Master
Mix (Life Technologies #4385612). hsa-miR-103a was used for
normalization of the results (Peltier and Latham, 2008).
Immunostaining
Cells were fixed in 4% paraformaldehyde (PFA) for 15 min, per-
meabilized in 0.5% Tween/PBS for 10 min, and blocked in
2.5% horse serum. Frozen placental sections were fixed in
acetone for 5 min. Immunostaining for 2102Ep, JEG-3,
and placental sections was performed using the Vectastain
ABC Elite kit. In brief, incubation in primary antibody over-
night was followed by biotinylated secondary antibody, and
then horseradish peroxidase (HRP)-conjugated ABC complex
for 30 min each. The fixed cells were washed 2 3 5 min
with 0.5% Tween/PBS between each incubation. HRP signal
was developed with 3,30- diaminobenzidine (Sigma-Aldrich
#D4168) and counterstained with Carazzi’s H&E. Human ESC
were stained by immunofluorescence with fluorophore-conju-
gated secondary antibodies, and counterstained with DAPI.
All primary and secondary antibodies are listed in Supple-
mental Experimental Procedures.
Flow Cytometry
To stain for surface proteins, we blocked cells with 0.25 mg/ml hu-
man immunoglobulin (Sigma #I4506), followed by incubation
with primary antibodies and Near-IR LIVE/DEAD Fixable Dead
Cell Stain Kit (Life Technologies #L10119) for 30 min at 4C. Cells
stained with non-conjugated antibodies were then incubated in
fluorophore-conjugated secondary antibodies (Life Technologies
#A-21202) for 30min at 4C. All stained cells were fixed in 2% PFA.
To stain for intracellular proteins, we fixed cells in Foxp3 fixa-
tion/permeabilization reagent (eBioscience #00-5521-00) for
30 min, and washed them with 1% FCS/PBS and then in Per-
meabilization Buffer (eBioscience #00–8333). Permeabilized cells
were blocked with human immunoglobulin, incubated with
anti-KRT7 mAbs for 15 min at room temperature, washed in Per-
meabilization Buffer, and fixed in 2% PFA. All antibodies are listed
in Supplemental Experimental Procedures. Data were acquired via
Cytek Development DxP 8 colors (488/637/561). All compensa-
tion was applied digitally after acquisition. The data were analyzed
using FlowJo (Tree Star).
Bisulfite Sequencing
To isolate VCT and EVT cells from two donors (GA 8 weeks), we
stained cells with 7AAD (eBioscience #00-6993-50) to exclude
dead cells and anti-CD45 mAb to remove leukocytes. EGFR+ VCT
and HLA-G+ EVT were sorted from the remaining fraction (Fig-
ure S1A) (Apps et al., 2011).
DNA from each sample was treated with bisulfite using the Epi-
Tect Bisulfite Kit (Qiagen #59110), according to themanufacturer’sthors
protocol. 10% of the resulting DNAwas used for the amplification
of the 432 to 3 bp region upstream of the ELF5 start site via
nested PCR.
The primer sequences were:Primer Name Sequence
hELF5-2b BiS 483F GGAAATGATGGATATTGAATTTGA
hELF5-2b BiS +31R CAATAAAAATAAAAACACCTATAACC
hELF5-2b BiS 432F GAGGTTTTAATATTGGGTTTATAATG
hELF5-2b BiS 3R ATAAATAACACCTACAAACAAATCCAmplicons were inserted into pGEM-T Easy vectors (Promega,
#A1360) and the products were used to transform Library
Efficiency DH5a Chemically Competent Cells (Invitrogen,
#18263012). Eight clones were sequenced for each cell line.SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental
Procedures, two figures, and two tables and can be found
with this article online at http://dx.doi.org/10.1016/j.stemcr.
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